Brain Imaging and Behavior

, Volume 12, Issue 2, pp 509–517 | Cite as

Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia

  • Natalie Matosin
  • Kelly Anne Newell
  • Yann Quidé
  • Jessica Lee Andrews
  • Nina Teroganova
  • Melissa Jayne Green
  • Francesca Fernandez
Original Research


GRM5 (coding for metabotropic glutamate receptor 5, mGluR5) is a promising target for the treatment of cognitive deficits in schizophrenia, but there has been little investigation of its association with cognitive and brain phenotypes within this disorder. We examined the effects of common genetic variation in GRM5 with cognitive function, hippocampal volume, and hippocampal mGluR5 protein levels in schizophrenia patients relative to healthy controls. Two independent GRM5 variants rs60954128 [C>T] and rs3824927 [G>T] were genotyped in a schizophrenia case/control cohort (n=249/261). High-resolution anatomical brain scans were available for a subset of the cohort (n=103 schizophrenia /78 control). All participants completed a standard set of neuropsychological tests. In a separate postmortem cohort (n=19 schizophrenia/20 controls), hippocampal mGluR5 protein levels were examined among individuals of different GRM5 genotypes. Schizophrenia minor allele carriers of rs60954128 had reduced right hippocampal volume relative to healthy controls of the same genotype (−12.3%); this effect was exaggerated in males with schizophrenia (−15.6%). For rs3824927, compared to major allele homozygotes, minor allele carriers with schizophrenia had lower Intelligence Quotients (IQ). Examination in hippocampal postmortem tissue showed no difference in mGluR5 protein expression according to genotype for either rs60954128 or rs3824927. While these genetic variants in GRM5 were associated with cognitive impairments and right hippocampal volume reduction in schizophrenia, they did not affect protein expression. Further study of these mechanisms may help to delineate new targets for the treatment of cognitive deficits in schizophrenia, and may be relevant to other disorders.


Metabotropic glutamate receptor 5 mGluR5 GRM5 Schizophrenia Case-control IQ 



This study was supported by a Grant-in-Aid held by Authors NM, KN and FF and the Daniel Beck Award held by Author NM, from the Schizophrenia Research Institute. The study used samples and data from the Australian Schizophrenia Research Bank (ASRB), funded by the Australian National Health and Medical Research Council (NHMRC) Enabling Grant (No. 386500) held by V. Carr, U. Schall, R. Scott, A. Jablensky, B. Mowry, P. Michie, S. Catts, F. Henskens and C. Pantelis (Chief Investigators), and the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, as well the Schizophrenia Research Institute, using an infrastructure grant from the NSW Ministry of Health. Authors NM and JA were supported by Ian Scott Scholarships from Australian Rotary Health. Author NT was supported by an Australian Postgraduate Award. Author MG was supported by an Australian National Health and Medical Research Council (NHMRC) Biomedical Career Development Fellowship (1061875). Postmortem brain tissues were received from the NSW Tissue Resource Centre, which is supported by the National Health and Medical Research Council of Australia, Schizophrenia Research Institute and the National Institute of Alcohol Abuse and Alcoholism [NIH (NIAA) R24AA012725]. The authors wish to thank P. Bitter and B. Yamasani from the Australian Cancer Research Foundation at The Garvan Institute of Medical Research, Sydney for their assistance with the MassARRAY genotyping assays, as well as A.M. Shepherd and I.C. Gould for assistance with structural imaging and Freesurfer processing. All authors report no financial relationships with commercial interests.

Compliance with ethical standards

Conflicts of interest

All authors declare that they have no conflicts of interest.

Informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, and the applicable revisions at the time of the investigation. Informed consent was obtained from all patients for being included in the study

Supplementary material

11682_2017_9712_MOESM1_ESM.pdf (167 kb)
ESM 1 (PDF 167 KB)


  1. Aickin, M., & Gensler, H. (1996). Adjusting for multiple testing when reporting research results: The Bonferroni vs Holm methods. American Journal of Public Health, 86(5), 726–728.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Attucci, S., Carla, V., Mannaioni, G., & Moroni, F. (2001). Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. British Journal of Pharmacology, 132(4), 799–806.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Ayala, J. E., Chen, Y., Banko, J. L., Sheffler, D. J., Williams, R., Telk, A. N., et al. (2009). mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology, 34(9), 2057–2071. doi: 10.1038/npp.2009.30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Ayalew, M., Le-Niculescu, H., Levey, D. F., Jain, N., Changala, B., Patel, S. D., et al. (2012). Convergent functional genomics of schizophrenia: From comprehensive understanding to genetic risk prediction. Molecular Psychiatry, 17(9), 887–905.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Beck, K., Javitt, D. C., & Howes, O. D. (2016). Targeting glutamate to treat schizophrenia: Lessons from recent clinical studies. Psychopharmacology, 233(13), 2425–2428.Google Scholar
  6. Colom, R., Stein, J. L., Rajagopalan, P., Martínez, K., Hermel, D., Wang, Y., et al. (2013). Hippocampal structure and human cognition: Key role of spatial processing and evidence supporting the efficiency hypothesis in females. Intelligence, 41(2), 129–140.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Devon, Anderson S., Teague, P., Muir, W., Murray, V., Pelosi, A., et al. (2001). The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Molecular Psychiatry, 6(3), 311.Google Scholar
  8. Doherty, J. L., & Owen, M. J. (2014). Genomic insights into the overlap between psychiatric disorders: Implications for research and clinical practice. Genome Medicine, 6(4), 29. doi: 10.1186/gm546.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Dölen, G., & Bear, M. F. (2008). Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. The Journal of Physiology, 586(6), 1503–1508.CrossRefPubMedGoogle Scholar
  10. Elia, J., Gai, X., Xie, H. M., Perin, J. C., Geiger, E., Glessner, J. T., et al. (2010). Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Molecular Psychiatry, 15(6), 637–646.CrossRefPubMedGoogle Scholar
  11. Goldstein, J. M., Cherkerzian, S., Tsuang, M. T., & Petryshen, T. L. (2013). Sex differences in the genetic risk for schizophrenia: History of the evidence for sex-specific and sex-dependent effects. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 162(7), 698–710.CrossRefGoogle Scholar
  12. Jia, Z., Lu, Y., Henderson, J., Taverna, F., Romano, C., Abramow-Newerly, W., et al. (1998). Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5. Learning & Memory, 5(4), 331–343. doi: 10.1101/lm.5.4.331.Google Scholar
  13. Kirov, G., Pocklington, A. J., Holmans, P., Ivanov, D., Ikeda, M., Ruderfer, D., et al. (2012). De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Molecular Psychiatry, 17(2), 142–153. doi: 10.1038/mp.2011.154.CrossRefPubMedGoogle Scholar
  14. Krijger, P.H.L., & de Laat, W. (2016). Regulation of disease-associated gene expression in the 3D genome. Nature Reviews Molecular Cell Biology. Accessed 24 January 2017.
  15. Kuntsi, J., Eley, T. C., Taylor, A., Hughes, C., Asherson, P., Caspi, A., & Moffitt, T. E. (2004). Co-occurrence of ADHD and low IQ has genetic origins. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 124(1), 41–47.CrossRefGoogle Scholar
  16. Loughland, C., Draganic, D., McCabe, K., Richards, J., Nasir, A., Allen, J., et al. (2010). Australian schizophrenia research Bank: A database of comprehensive clinical, endophenotypic and genetic data for aetiological studies of schizophrenia. Australian and New Zealand Journal of Psychiatry, 44(11), 1029–1035.PubMedGoogle Scholar
  17. Malhotra, A. K., Pinals, D. A., Weingartner, H., Sirocco, K., Missar, C. D., Pickar, D., & Breier, A. (1996). NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14(5), 301–307. doi: 10.1016/0893-133x(95)00137-3.CrossRefPubMedGoogle Scholar
  18. Manahan-Vaughan, D., & Braunewell, K. H. (2005). The metabotropic glutamate receptor, mGluR5, is a key determinant of good and bad spatial learning performance and hippocampal synaptic plasticity. Cerebral Cortex, 15(11), 1703–1713.CrossRefPubMedGoogle Scholar
  19. Mannaioni, G., Marino, M. J., Valenti, O., Traynelis, S. F., & Conn, P. J. (2001). Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. The Journal of Neuroscience, 21(16), 5925–5934.PubMedGoogle Scholar
  20. Matosin, N., Fernandez-Enright, F., Lum, J. S., Andrews, J. L., Engel, M., Huang, X.-F., & Newell, K. A. (2015a). Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia. Schizophrenia Research, 166(1–3), 212–218. doi: 10.1016/j.schres.2015.05.001.CrossRefPubMedGoogle Scholar
  21. Matosin, N., Fernandez-Enright, F., Lum, J. S., & Newell, K. A. (2015b). Shifting towards a model of mGluR5 dysregulation in schizophrenia: Consequences for future schizophrenia treatment. Neuropharmacology. doi: 10.1016/j.neuropharm.2015.08.003.PubMedGoogle Scholar
  22. Millar, J. K., Brown, J., Maule, J. C., Shibasaki, Y., Christie, S., Lawson, D., et al. (1998). A long-range restriction map across 3 Mb of the chromosome 11 breakpoint region of a translotion linked to schizophrenia: Localization of the breakpoint and the search for neighbouring genes. Psychiatric Genetics, 8(3), 175–182.CrossRefPubMedGoogle Scholar
  23. Minh, T. N. N. (2014). Relationship between subcortical volumes and cognitive abilities in young healthy adults. Vietnam: International University HCMC Retrieved from Scholar
  24. Mukherjee, S., & Manahan-Vaughan, D. (2013). Role of metabotropic glutamate receptors in persistent forms of hippocampal plasticity and learning. Neuropharmacology, 66, 65–81.CrossRefPubMedGoogle Scholar
  25. Randolph, C. (1998). RBANS manual: Repeatable battery for the assessment of neuropsychological status. San Antonio, TX: The Psychological Corporation.Google Scholar
  26. Ripke, S., O’Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., et al. (2013). Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nature Genetics, 45(10), 1150–1159. doi: 10.1038/ng.2742.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Ripke, S., Sanders, A. R., Kendler, K. S., Levinson, D. F., Sklar, P., Holmans, P. A., et al. (2011). Genome-wide association study identifies five new schizophrenia loci. Nature Genetics, 43(10), 969–976. doi: 10.1038/ng.940.CrossRefGoogle Scholar
  28. Schizophrenia Working Group of the Psychiatric Genomics Consortium. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 511(7510), 421–427.CrossRefPubMedCentralGoogle Scholar
  29. Sherry, S. T., Ward, M.-H., Kholodov, M., Baker, J., Phan, L., Smigielski, E. M., & Sirotkin, K. (2001). dbSNP: The NCBI database of genetic variation. Nucleic Acids Research, 29(1), 308–311.CrossRefPubMedPubMedCentralGoogle Scholar
  30. Spreen, O. (1998). A compendium of neuropsychological tests: Administration, norms, and commentary. New York: Oxford University Press.Google Scholar
  31. Sullivan, K., Hatton, D., Hammer, J., Sideris, J., Hooper, S., Ornstein, P., & Bailey, D. (2006). ADHD symptoms in children with FXS. American Journal of Medical Genetics Part A, 140(21), 2275–2288.CrossRefPubMedGoogle Scholar
  32. Tabor, H. K., Risch, N. J., & Myers, R. M. (2002). Candidate-gene approaches for studying complex genetic traits: Practical considerations. Nature Reviews. Genetics, 3(5), 391–397. doi: 10.1038/nrg796.PubMedGoogle Scholar
  33. Timms, A. E., Dorschner, M. O., Wechsler, J., Choi, K. Y., Kirkwood, R., Girirajan, S., et al. (2013). Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA psychiatry (Chicago, Ill.), 70(6), 582–590. doi: 10.1001/jamapsychiatry.2013.1195.CrossRefGoogle Scholar
  34. Tsai, G., Van Kammen, D. P., Chen, S., Kelley, M. E., Grier, A., & Coyle, J. T. (1998). Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biological Psychiatry, 44(8), 667–674.CrossRefPubMedGoogle Scholar
  35. Wechsler, D. (1997). WAIS-III: Administration and scoring manual: Wechsler adult intelligence scale. Psychological Corporation.Google Scholar
  36. Wechsler, D. (2001). Wechsler test of adult reading: WTAR. Psychological Corporation.Google Scholar
  37. Wilkening, S., Chen, B., Bermejo, J. L., & Canzian, F. (2009). Is there still a need for candidate gene approaches in the era of genome-wide association studies? Genomics, 93(5), 415–419.CrossRefPubMedGoogle Scholar
  38. Yang, Y. S., Marder, S. R., & Green, M. F. (2016). Repurposing drugs for cognition in schizophrenia. Clinical Pharmacology & Therapeutics, n/a-n/a. doi: 10.1002/cpt.529

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Natalie Matosin
    • 1
    • 2
  • Kelly Anne Newell
    • 1
  • Yann Quidé
    • 2
    • 3
  • Jessica Lee Andrews
    • 1
  • Nina Teroganova
    • 2
    • 3
  • Melissa Jayne Green
    • 2
    • 3
  • Francesca Fernandez
    • 1
    • 4
  1. 1.Faculty of Science, Medicine and Health, Faculty of Social Sciences, and the Illawarra Health and Medical Research InstituteUniversity of WollongongWollongongAustralia
  2. 2.School of Psychiatry, Faculty of MedicineUniversity of New South WalesSydneyAustralia
  3. 3.Neuroscience Research AustraliaSydneyAustralia
  4. 4.School of Science, Faculty of Health SciencesAustralian Catholic UniversityBrisbaneAustralia

Personalised recommendations